Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| microglial cell | 17 studies | 50% ± 23% | |
| astrocyte | 11 studies | 37% ± 16% | |
| macrophage | 10 studies | 24% ± 8% | |
| retinal rod cell | 8 studies | 36% ± 11% | |
| alveolar macrophage | 6 studies | 28% ± 8% | |
| amacrine cell | 6 studies | 32% ± 8% | |
| retinal cone cell | 6 studies | 46% ± 18% | |
| retina horizontal cell | 5 studies | 43% ± 14% | |
| Mueller cell | 5 studies | 49% ± 14% | |
| retinal bipolar neuron | 4 studies | 55% ± 15% | |
| retinal ganglion cell | 4 studies | 42% ± 19% | |
| basal cell | 4 studies | 34% ± 17% | |
| oligodendrocyte | 4 studies | 29% ± 6% | |
| OFF-bipolar cell | 3 studies | 48% ± 14% | |
| ON-bipolar cell | 3 studies | 51% ± 17% | |
| retinal pigment epithelial cell | 3 studies | 42% ± 14% | |
| monocyte | 3 studies | 21% ± 4% | |
| ciliated cell | 3 studies | 37% ± 8% | |
| myeloid cell | 3 studies | 25% ± 7% | |
| rod bipolar cell | 3 studies | 66% ± 5% | |
| fibroblast | 3 studies | 17% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 4693.70 | 2639 / 2642 | 97% | 80.53 | 681 / 705 |
| thymus | 100% | 4822.46 | 652 / 653 | 95% | 239.06 | 576 / 605 |
| adrenal gland | 95% | 1779.28 | 245 / 258 | 84% | 47.22 | 193 / 230 |
| ovary | 78% | 1091.27 | 141 / 180 | 98% | 216.93 | 420 / 430 |
| breast | 96% | 2708.47 | 442 / 459 | 76% | 41.20 | 850 / 1118 |
| bladder | 95% | 2445.33 | 20 / 21 | 66% | 44.24 | 335 / 504 |
| prostate | 96% | 1696.87 | 236 / 245 | 54% | 19.43 | 272 / 502 |
| pancreas | 52% | 413.52 | 169 / 328 | 92% | 50.15 | 163 / 178 |
| lung | 93% | 1624.95 | 537 / 578 | 46% | 16.78 | 529 / 1155 |
| skin | 54% | 601.27 | 978 / 1809 | 79% | 65.58 | 375 / 472 |
| kidney | 44% | 501.43 | 39 / 89 | 88% | 92.24 | 795 / 901 |
| intestine | 90% | 1256.98 | 867 / 966 | 41% | 16.04 | 217 / 527 |
| esophagus | 67% | 1091.32 | 970 / 1445 | 54% | 27.24 | 99 / 183 |
| muscle | 99% | 3177.69 | 795 / 803 | 0% | 0 | 0 / 0 |
| spleen | 97% | 1638.66 | 234 / 241 | 0% | 0 | 0 / 0 |
| uterus | 60% | 948.94 | 102 / 170 | 37% | 19.69 | 168 / 459 |
| blood vessel | 96% | 2443.64 | 1285 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 94% | 1761.80 | 1126 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 93% | 84.58 | 74 / 80 |
| stomach | 42% | 422.39 | 149 / 359 | 43% | 18.70 | 123 / 286 |
| heart | 83% | 1171.88 | 716 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 48% | 13.86 | 14 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 24% | 10.65 | 11 / 45 |
| peripheral blood | 13% | 187.16 | 118 / 929 | 0% | 0 | 0 / 0 |
| liver | 0% | 0 | 0 / 226 | 9% | 3.05 | 35 / 406 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0010944 | Biological process | negative regulation of transcription by competitive promoter binding |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0032922 | Biological process | circadian regulation of gene expression |
| GO_0010832 | Biological process | negative regulation of myotube differentiation |
| GO_0009952 | Biological process | anterior/posterior pattern specification |
| GO_0050767 | Biological process | regulation of neurogenesis |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO_0043425 | Molecular function | bHLH transcription factor binding |
| GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
| GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
| GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0070888 | Molecular function | E-box binding |
| GO_0043426 | Molecular function | MRF binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0042826 | Molecular function | histone deacetylase binding |
| Gene name | BHLHE41 |
| Protein name | Basic helix-loop-helix family, member e41 (Basic helix-loop-helix protein 3 isoform 1) Class E basic helix-loop-helix protein 41 (bHLHe41) (Class B basic helix-loop-helix protein 3) (bHLHb3) (Differentially expressed in chondrocytes protein 2) (hDEC2) (Enhancer-of-split and hairy-related protein 1) (SHARP-1) |
| Synonyms | BHLHB3 SHARP1 DEC2 |
| Description | FUNCTION: Transcriptional repressor involved in the regulation of the circadian rhythm by negatively regulating the activity of the clock genes and clock-controlled genes . Acts as the negative limb of a novel autoregulatory feedback loop (DEC loop) which differs from the one formed by the PER and CRY transcriptional repressors (PER/CRY loop). Both these loops are interlocked as it represses the expression of PER1 and in turn is repressed by PER1/2 and CRY1/2. Represses the activity of the circadian transcriptional activator: CLOCK-BMAL1 heterodimer by competing for the binding to E-box elements (5'-CACGTG-3') found within the promoters of its target genes . Negatively regulates its own expression and the expression of DBP and BHLHE41/DEC2. Acts as a corepressor of RXR and the RXR-LXR heterodimers and represses the ligand-induced RXRA/B/G, NR1H3/LXRA, NR1H4 and VDR transactivation activity. Inhibits HNF1A-mediated transactivation of CYP1A2, CYP2E1 AND CYP3A11 (By similarity). . |
| Accessions | ENST00000242728.5 Q8TAT1 Q9C0J9 |